This second issue revisits the impact EMPA-REG OUTCOME had on clinical
practice and helps readers discover how it gives life back to patients
through its cardiovascular indication. Learn how it was approved and the
mechanisms for its cardiovascular benefits.
Dropping aspirin after 3 months of dual therapy with ticagrelor reduced bleeding in patients with diabetes who have undergone PCI* vs taking both agents for 1 year, the TWILIGHT-DM** study has shown, consistent with benefits seen in TWILIGHT for other high-risk patients.
This is the first issue in a series of five
articles celebrating the fifth anniversary of EMPA-REG OUTCOME’s trial data
release. This issue brings insight to the trial’s background, study design and
In a dinner symposium organised by Boehringer Ingelheim Malaysia, Dr Alice Cheng spoke on how cardiovascular outcome trials (CVOTs) have evolved and impacted the use of antihyperglycaemic agents such as sodium-glucosecotransporter-2 inhibitors (SGLT-2i) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in clinical practice.
At the AstraZeneca sponsored-symposium, held in conjunction with Diabetes Asia 2019, a panel of distinguished speakers spoke about the importance of preventing cardiovascular (CV) and renal complications in patients with type 2 diabetes mellitus (T2DM), in addition to addressing glucose control. Chaired by Professor Dato’ Dr Mafauzy Mohamed, the panel discussed updated outcomes of landmark studies supporting the benefit of dapagliflozin (Forxiga®, AstraZeneca) in patients with T2DM.
In a lecture tour series organised by Boehringer Ingelheim Malaysia, Professor Michael Cummings spoke on the latest linagliptin analyses that shed new light on the long-term safety profile of the dipeptidyl peptidase-4 (DPP-4) inhibitor across a broad range of patients with type 2 diabetes (T2D).
At a recent Boehringer Ingelheim-sponsored symposium held in conjunction with the 10th Malaysian Endocrine and Metabolic Society Annual Congress, two distinguished speakers spoke on the latest updates in glucose-lowering therapy for the treatment for type 2 diabetes mellitus (T2DM) and highlighted some important cardiovascular outcome trial results of these antidiabetic agents.
At the recent 10th Malaysian Endocrine and Metabolic Society (MEMS) Annual Congress(MAC) held in Hilton Kuala Lumpur, Dr Wong Ming, a consultant endocrinologist from Sunway Medical Centre, spoke on the role of non–high-density lipoprotein cholesterol (non–HDL-c) as an emerging marker and treatment target for cardiovascular (CV) disease. Additionally, she also highlighted the role of fenofibrate in delaying and preventing diabetic retinopathy (DR).
At a recent Abbott lunch symposium held in conjunction with the joint 12th International Diabetes FederationWestern Pacific Region Congress & 10th Asian Association for the Study of Diabetes Scientific Meeting in KualaLumpur, Professor Shashank R. Joshi extensively discussed the issue of diabetes in obesity and the role of nutritionalintervention in addressing this growing problem.